Hainan FTP Pharma Policy: Partner Due Diligence

The most useful question is not “Does Hainan Free Trade Port policy apply?” It is: “Which policy, for which entity, product, activity, location and period—and what must be verified before the policy can matter to this project?”

1. The short answer

Hainan’s official materials describe an environment that encourages pharmaceutical production, generic-drug R&D and production, drug marketing-authorisation-holder operations, advanced pharmaceutical and biological manufacturing, and related research activity. [2] This helps an overseas partner understand the policy setting. It does not establish a company’s eligibility, a product’s regulatory status, a customs treatment, a tax outcome, a manufacturing fit, a supply commitment or a project acceptance.

2. What the policy context can show

The Hainan government’s medicine-and-healthcare overview records seven market-access measures introduced in 2021, including pharmaceutical market-access facilitation and eased entry barriers for CROs. [1] The 2024 encouraged-industries catalog is effective from 1 March 2024 and states that it applies to enterprises operating in the Hainan Free Trade Port; it separately notes that foreign-invested enterprises should follow the encouraged-industries catalog for foreign investment. [2]

For a partner, those statements are best used as a research map: identify the exact intended legal role and activity first, then have the responsible tax, customs, regulatory and legal advisers determine whether any specific rule applies.

3. Where scope matters most: Boao Lecheng is not all of Hainan

“Zero-tariff” medicines and medical devices are often cited without their boundaries. Official Hainan materials describe the policy as applying to eligible medical institutions, medical universities and pharmaceutical research institutes in the Boao Lecheng International Medical Tourism Pilot Zone, for qualifying imports and permitted use cases. [3] The provincial management measures specify that this framework applies only in that pilot zone. [3]

Accordingly, this special measure must not be presented as a general manufacturing, export or commercial benefit for every pharmaceutical business in Hainan. It is a policy topic to verify against the specific entity, activity and use scenario.

4. How to use Hainan’s location information responsibly

Official Hainan materials describe the province as connecting the Chinese mainland and Southeast Asia, and identify it as a maritime corridor between the Beibu Gulf and the South China Sea. [4] This can be relevant context when an overseas partner is mapping regional dialogue, travel, logistics or market research. It is not evidence by itself of a route, lead time, customs clearance outcome, distribution capability or market access for a proposed pharmaceutical product.

5. A partner diligence sequence before drawing conclusions

6. A narrow R&D-materials example

Hainan’s official high-tech-industry overview describes a pilot joint regulatory innovation mechanism for importing biopharmaceutical R&D materials. It states that eligible biopharmaceutical enterprises may import those R&D materials without applying for customs clearance of imported drugs. [6]

This is a narrow research-materials example, not a finished-product, manufacturing, export or general project policy. It does not establish that Hainan Hailing, a site, a product or a proposed project is eligible, approved, covered, ready to proceed or entitled to any outcome. Eligibility and operational conditions must be confirmed for the exact entity, activity, product, location and period with the responsible authorities and advisers.

7. A separate drug-regulatory check: who owns which duty?

On 23 July 2026, the Hainan Medical Products Administration published its 2026 responsibility list for drug, medical-device and cosmetics businesses (document Qiong Yao Jian Zhu Chan〔2026〕No. 125, dated 22 July). This is a regulator-issued summary of responsibilities under applicable drug rules—not a Free Trade Port tax or customs incentive. For contract manufacturing, the list says the marketing authorisation holder (MAH) must select a legally qualified manufacturer, sign written manufacturing and quality agreements, assign dedicated quality personnel, periodically review the contractor’s quality system, transfer the full production technical package and validate the process transfer. It also says the MAH retains the marketing-release duty and primary responsibility for the quality of outsourced products. [7]

The receiving manufacturer, in turn, must verify the contracting party’s legal qualifications, operate within its approved manufacturing-licence scope, avoid unauthorised re-subcontracting, follow the applicable standards and approved process, and promptly notify the MAH in writing of deviations, material changes or quality abnormalities. [7]

For a real project, partners can use this as a checklist: identify the MAH and each manufacturing site; verify the exact licence scope and product-specific regulatory status; map technical-transfer, validation, change-control, audit, batch-release and record-retention responsibilities in the quality agreement; and check the current rules with the responsible authority and advisers. This general list does not establish Hainan Hailing’s qualification, any site or product status, capacity, inspection outcome, policy eligibility or project acceptance.

8. A narrowly scoped post-marketing change pilot—not a general fast track

In a notice dated 17 December 2025, the Hainan Medical Products Administration described an advance-service pilot for post-marketing major pharmaceutical changes to chemical drugs, including APIs. It is directed to eligible Hainan-based marketing authorisation holders and API registrants. Specified categories are excluded, including changes requiring clinical studies, certain supplier changes where the post-change registration status is “I”, and consistency-evaluation applications. For covered supplemental applications requiring inspection and testing, the stated review timeline is reduced from 200 to 60 working days. [8]

A separate regulator update published 4 September 2026 reports that, as of 31 August, 42 of 42 scheduled milestones under the “1+4+N” industry-support policy and 27 of 27 “No. 1 defense line” safety-supervision tasks had been completed. These are implementation milestones for the provincial regulator—not a company-specific incentive, site qualification or proof that a particular project has entered or benefited from the pilot. [9]

At a Hainan Provincial Information Office press conference on 30 June 2026, the provincial drug regulator reported that the pilot's first supported post-marketing major-change application received NMPA approval on 19 March 2026. It also reported that 12 products had received one-to-one advance guidance by 31 May 2026. These are dated outcomes of the provincial program—not evidence that Hainan Hailing, a named product or a future application meets the pilot's criteria or will receive a similar result. [12]

If the provincial notice is temporarily unavailable, the NMPA approval of the Hainan pilot and the NMPA-hosted English policy overview provide independent official checks for the pilot designation and national 200-to-60-working-day framework. They do not replace the provincial notice for its local eligibility, exclusions or application process.

For due diligence, verify the applicant’s legal status and location, the exact change category, exclusions, required dossier and inspection/testing steps with the responsible Hainan service centre and CDE. The stated 60-working-day review target is not a universal drug-approval timeline and does not guarantee acceptance, approval, eligibility or commercial benefit. This update makes no claim that Hainan Hailing or any named product is eligible or has used the pilot.

Frequently asked questions

Authoritative sources

1. Hainan Provincial People’s Government — Medicine & Healthcare (updated 27 June 2025)
2. Hainan Provincial People’s Government — Hainan Free Trade Port Encouraged Industries Catalog (2024 Edition)
3. Hainan Provincial People’s Government — Zero-tariff medicine imports in Hainan FTP (policy scope report)
4. Hainan Provincial People’s Government — Location
5. Hainan Provincial People’s Government — Processing value-added duty-exemption policy update
6. Hainan Provincial People’s Government — High-tech industries: biopharmaceutical R&D-materials pilot (updated 27 June 2025)
7. Hainan Medical Products Administration — 2026 Responsibility List for Drug, Medical Device and Cosmetics Businesses (published and dated 22 July 2026)
8. 海南省药品监督管理局：优化药品补充申请审评审批程序改革试点通告（2025年第34号，2025年12月17日）
9. 海南省药品监督管理局：“1+4+N”产业支持政策与“1号防线”监管任务进展（2026年9月4日；数据截至8月31日）
10. National Medical Products Administration — approval for Jilin and Hainan supplemental-application pilots (9 December 2025)
11. National Medical Products Administration English site — State Council reform opinions, supplemental-application pilot framework (updated 25 March 2025)
12. Hainan Provincial Information Office — pharmaceutical regulatory reform press conference transcript (30 June 2026; pilot guidance count as of 31 May 2026)

This article is for general business discussion. It is not legal, tax, customs, regulatory or medical advice. Requirements should be confirmed with responsible parties and applicable authorities.